Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 Exhibit 1.1
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 3.3 Exhibit 3.3
- 3.4 Exhibit 3.4
- 4.1 Exhibit 4.1
- 4.2 Exhibit 4.2
- 4.3 Exhibit 4.3
- 4.4 Exhibit 4.4
- 5.1 Exhibit 5.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 10.17 Exhibit 10.17
- 10.18 Exhibit 10.18
- 10.19 Exhibit 10.19
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 10.27 Exhibit 10.27
- 10.28 Exhibit 10.28
- 10.29 Exhibit 10.29
- 10.30 Exhibit 10.30
- 10.31 Exhibit 10.31
- 10.32 Exhibit 10.32
- 10.33 Exhibit 10.33
- 10.34 Exhibit 10.34
- 10.35 Exhibit 10.35
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- EX-FILING FEES Ex-filing Fees
Associated filings
- 13 Jul 23 424B4 Prospectus supplement with pricing info
- 12 Jul 23 EFFECT Notice of effectiveness
- 8 Jun 23 S-1/A IPO registration (amended)
- 1 Jun 23 S-1/A IPO registration (amended)
- 19 May 23 S-1/A IPO registration (amended)
-
28 Apr 23 S-1/A IPO registration (amended)
- 3 Apr 23 S-1/A IPO registration (amended)
- 31 Jan 23 S-1 IPO registration
SXTP similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation in the Registration Statement of 60 Degrees Pharmaceuticals, Inc. (F/K/A 60 Degrees Pharmaceuticals, LLC) on Form S-1 Amendment No. 2 of our report dated April 3, 2023 which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the financial statements of 60 Degrees Pharmaceuticals, Inc. as of December 31, 2022 and 2021, and for the each of the two years in the period ended December 31, 2022.
We also consent to the reference to us under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ RBSM LLP |
Las Vegas, Nevada
April 28, 2023